Citigroup Inc Landos Biopharma, Inc. Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	BUY	$0.22 - $0.51 $5 - $12	24 Added 4.85%	519 $0
Q3 2022 Nov 10, 2022	SELL	$0.67 - $1.26 $164 - $309	-246 Reduced 33.2%	495 $0
Q2 2022 Aug 10, 2022	SELL	$0.6 - $1.5 $1,239 - $3,097	-2,065 Reduced 73.59%	741 $1,000
Q1 2022 May 12, 2022	BUY	$1.44 - $5.22 $515 - $1,868	358 Added 14.62%	2,806 $4,000
Q4 2021 Feb 10, 2022	BUY	$4.7 - $15.0 $8,930 - $28,500	1,900 Added 346.72%	2,448 $12,000
Q3 2021 Nov 10, 2021	BUY	$9.77 - $15.77 $5,353 - $8,641	548 New	548 $8,000

Ticker LABP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,254,900
Description
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of u...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.